Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Germany says AstraZeneca lawsuit "not priority" for now

Fri, 23rd Apr 2021 12:53

(Alliance News) - Germany would support legal action against AstraZeneca PLC for under-delivering Covid-19 vaccine doses to the EU, but the priority now should be on securing the jabs, Health Minister Jens Spahn said Friday.

The European Commission is considering a lawsuit against the Swedish-British pharmaceutical giant for so far delivering just 31 million of the 120 million doses it had promised, according to EU diplomats.

Asked if he thought the lawsuit was a good idea, Spahn said: "If (the commission) decides to take legal action, then yes... but it's much more important to me that I get this vaccine."

Germany wants to "cooperate with AstraZeneca to get as many deliveries as possible as quickly as possible", he said, adding that legal issues are "not yet a priority in this phase of the pandemic".

EU diplomats said Thursday no final decision has been taken on legal action but the EU executive has informed member state envoys and wants them to confirm whether they would back a lawsuit.

"As you know, AstraZeneca is not delivering the number of doses which have been agreed upon in the contract... This is one of the reasons why we keep our options open together with member states to take any further steps," commission spokesman Stefan De Keersmaecker said on Thursday.

One diplomat told AFP that "not all member states are in agreement" on taking the company to court, stressing that their aim was simply to have AstraZeneca deliver the doses it had promised in its contract.

Public confidence in the AstraZeneca jab has taken a blow after the European Medicines Agency, the bloc's regulator, said it was likely linked to a very rare form of blood clot affecting the brain. 

The EMA and the commission have not changed their stance on a general use of AstraZeneca, saying its benefits outweigh the risks, but several EU countries have restricted its use to older citizens.

The EU, however, is now increasingly relying on the BioNTech SE/Pfizer Inc vaccine for its rollout, which has been accelerating since the end of March.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...

8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4% *

8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...

8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...

8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.